Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2016

Open Access 01-12-2016 | Research article

Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis

Authors: Xavier Giffroy, Nathalie Maes, Adelin Albert, Pierre Maquet, Jean-Michel Crielaard, Dominique Dive

Published in: BMC Neurology | Issue 1/2016

Login to get access

Abstract

Background

Functional biomarkers able to identify multiple sclerosis (MS) patients at high risk of fast disability progression are lacking. The aim of this study was to evaluate the ability of multimodal (upper and lower limbs motor, visual, lower limbs somatosensory) evoked potentials (EP) to monitor disease course and identify patients exposed to unfavourable evolution.

Methods

One hundred MS patients were assessed with visual, somatosensory and motor EP and rated on the Expanded Disability Status Scale (EDSS) at baseline (T0) and about 6 years later (T1). The Spearman correlation (rS) was used to evaluate the relationship between conventional EP scores and clinical findings. Multiple (logistic) regression analysis estimated the predictive value of baseline electrophysiological data for three clinical outcomes: EDSS, annual EDSS progression, and the risk of EDSS worsening.

Results

In contrast to longitudinal correlations, cross-sectional correlations between the different EP scores and EDSS were all significant (0.33 ≤ rS < 0.67, p < 0.001). Baseline global EP score and EDSS were highly significant predictors (p < 0.0001) of EDSS progression 6 years later. The baseline global EP score was found to be an independent predictor of the EDSS annual progression rate (p < 0.001), and of the risk of disability progression over time (p < 0.005). Based on a ROC curve determination, we defined a Global EP Score cut off point (17/30) to identify patients at high risk of disability progression illustrated by a positive predictive value of 70 %.

Conclusion

This study provides a proof of the concept that electrophysiology could be added to MRI and used as another complementary prognostic tool in MS patients.
Appendix
Available only for authorised users
Literature
1.
Hutchinson M. Evoked Potentials Are of Little Use in the Diagnosis or Monitoring of Ms: Commentary. Mult Scler. 2013;19(14):1824–5.CrossRefPubMed
2.
Beer S, Rosler KM, Hess CW. Diagnostic Value of Paraclinical Tests in Multiple Sclerosis: Relative Sensitivities and Specificities for Reclassification According to the Poser Committee Criteria. J Neurol Neurosurg Psychiatry. 1995;59(2):152–9.CrossRefPubMedPubMedCentral
3.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the Mcdonald Criteria. Ann Neurol. 2011;69(2):292–302.
4.
Comi G, Leocani L, Medaglini S, Locatelli T, Martinelli V, Santuccio G, Rossi P. Measuring Evoked Responses in Multiple Sclerosis. Mult Scler. 1999;5(4):263–7.CrossRefPubMed
5.
La Mantia L, Riti F, Milanese C, Salmaggi A, Eoli M, Ciano C, Avanzini G. Serial Evoked Potentials in Multiple Sclerosis Bouts. Relation to Steroid Treatment. Ital J Neurol Sci. 1994;15(7):333–40.CrossRefPubMed
6.
Nuwer MR, Packwood JW, Myers LW, Ellison GW. Evoked Potentials Predict the Clinical Changes in a Multiple Sclerosis Drug Study. Neurology. 1987;37(11):1754–61.CrossRefPubMed
7.
Feuillet L, Pelletier J, Suchet L, Rico A, Ali Cherif A, Pouget J, Attarian S. Prospective Clinical and Electrophysiological Follow-up on a Multiple Sclerosis Population Treated with Interferon Beta-1 A: A Pilot Study. Mult Scler. 2007;13(3):348–56.CrossRefPubMed
8.
Meuth SG, Bittner S, Seiler C, Gobel K, Wiendl H. Natalizumab Restores Evoked Potential Abnormalities in Patients with Relapsing-Remitting Multiple Sclerosis. Mult Scler. 2011;17(2):198–203.CrossRefPubMed
9.
Horton L, Conger A, Conger D, Remington G, Frohman T, Frohman E, E, Greenberg B. Effect of 4-Aminopyridine on Vision in Multiple Sclerosis Patients with Optic Neuropathy. Neurology. 2013;80(20):1862–6.
10.
Zeller D, Reiners K, Brauninger S, Buttmann M. Central Motor Conduction Time May Predict Response to Fampridine in Patients with Multiple Sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(6):707–9.CrossRefPubMedPubMedCentral
11.
O’Connor P, Marchetti P, Lee L, Perera M. Evoked Potential Abnormality Scores Are a Useful Measure of Disease Burden in Relapsing-Remitting Multiple Sclerosis. Ann Neurol. 1998;44(3):404–7.CrossRefPubMed
12.
Zivadinov R, Leist TP. Clinical-Magnetic Resonance Imaging Correlations in Multiple Sclerosis. J Neuroimaging. 2005;15(4 Suppl):10S–21.CrossRefPubMed
13.
Kesselring J, Miller DH, MacManus DG, Johnson G, Milligan NM, Scolding N, Compston DA, McDonald WI. Quantitative Magnetic Resonance Imaging in Multiple Sclerosis: The Effect of High Dose Intravenous Methylprednisolone. J Neurol Neurosurg Psychiatry. 1989;52(1):14–7.CrossRefPubMedPubMedCentral
14.
15.
Comi G, Locatelli T, Leocani L, Medaglini S, Rossi P, Martinelli V. Can Evoked Potentials Be Useful in Monitoring Multiple Sclerosis Evolution? Electroencephalogr Clin Neurophysiol Suppl. 1999;50:349–57.PubMed
16.
Jung P, Beyerle A, Ziemann U. Multimodal Evoked Potentials Measure and Predict Disability Progression in Early Relapsing-Remitting Multiple Sclerosis. Mult Scler. 2008;14(4):553–6.CrossRefPubMed
17.
Leocani L, Rovaris M, Boneschi FM, Medaglini S, Rossi P, Martinelli V, Amadio S, Comi G. Multimodal Evoked Potentials to Assess the Evolution of Multiple Sclerosis: A Longitudinal Study. J Neurol Neurosurg Psychiatry. 2006;77(9):1030–5.CrossRefPubMedPubMedCentral
18.
Fuhr P, Borggrefe-Chappuis A, Schindler C, Kappos L. Visual and Motor Evoked Potentials in the Course of Multiple Sclerosis. Brain. 2001;124(Pt 11):2162–8.CrossRefPubMed
19.
Schlaeger R, D’Souza M, Schindler C, Grize L, Kappos L, Fuhr P. Electrophysiological Markers and Predictors of the Disease Course in Primary Progressive Multiple Sclerosis. Mult Scler. 2014;20(1):51–6.CrossRefPubMed
20.
Margaritella N, Mendozzi L, Garegnani M, Colicino E, Gilardi E, Deleonardis L, Tronci F, Pugnetti L. Sensory Evoked Potentials to Predict Short-Term Progression of Disability in Multiple Sclerosis. Neurol Sci. 2012;33(4):887–92.CrossRefPubMed
21.
Ramanathan S, Lenton K, Burke T, Gomes L, Storchenegger K, Yiannikas C, Vucic S. The Utility of Multimodal Evoked Potentials in Multiple Sclerosis Prognostication. J Clin Neurosci. 2013;20(11):1576–81.CrossRefPubMed
22.
Margaritella N, Mendozzi L, Garegnani M, Nemni R, Colicino E, Gilardi E, Pugnetti L. Exploring the Predictive Value of the Evoked Potentials Score in Ms within an Appropriate Patient Population: A Hint for an Early Identification of Benign Ms? BMC Neurol. 2012;12:80.CrossRefPubMedPubMedCentral
23.
Bednarik J, Kadanka Z. Multimodal Sensory and Motor Evoked Potentials in a Two-Year Follow-up Study of Ms Patients with Relapsing Course. Acta Neurol Scand. 1992;86(1):15–8.CrossRefPubMed
24.
Aminoff MJ, Davis SL, Panitch HS. Serial Evoked Potentials Studies in Patients with Definite Multiple Sclerosis. Arch Neurol. 1984;44:1232–6.
25.
26.
Sharrack B, Hughes RA, Soudain S, Dunn G. The Psychometric Properties of Clinical Rating Scales Used in Multiple Sclerosis. Brain. 1999;122(Pt 1):141–59.CrossRefPubMed
27.
Kallmann BA, Fackelmann S, Toyka KV, Rieckmann P, Reiners K. Early Abnormalities of Evoked Potentials and Future Disability in Patients with Multiple Sclerosis. Mult Scler. 2006;12(1):58–65.CrossRefPubMed
28.
McGuigan C. Evoked Potentials Are of Little Use in the Diagnosis or Monitoring of Ms: Yes. Mult Scler. 2013;19(14):1820–1.CrossRefPubMed
29.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50(1):121–7.CrossRefPubMed
30.
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic Criteria for Multiple Sclerosis: 2005 Revisions to the “Mcdonald Criteria”. Ann Neurol. 2005;58(6):840–6.
31.
Kurtzke JF. Rating Neurologic Impairment in Multiple Sclerosis: An Expanded Disability Status Scale (Edss). Neurology. 1983;33(11):1444–52.CrossRefPubMed
32.
O’Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, Kendall BE, Rudge P, McDonald WI, Miller DH. The Prognostic Value of Brain Mri in Clinically Isolated Syndromes of the Cns. A 10-Year Follow-Up. Brain. 1998;121(Pt 3):495–503.CrossRefPubMed
33.
Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH. Disability and T2 Mri Lesions: A 20-Year Follow-up of Patients with Relapse Onset of Multiple Sclerosis. Brain. 2008;131(Pt 3):808–17.CrossRefPubMed
34.
Li DK, Held U, Petkau J, Daumer M, Barkhof F, Fazekas F, Frank JA, Kappos L, Miller DH, Simon JH, Wolinsky JS, Filippi M, Sylvia Lawry Centre for MSR. Mri T2 Lesion Burden in Multiple Sclerosis: A Plateauing Relationship with Clinical Disability. Neurology. 2006;66(9):1384–9.CrossRefPubMed
35.
Neema M, Stankiewicz J, Arora A, Dandamudi VS, Batt CE, Guss ZD, Al-Sabbagh A, Bakshi R. T1- and T2-Based Mri Measures of Diffuse Gray Matter and White Matter Damage in Patients with Multiple Sclerosis. J Neuroimaging. 2007;17 Suppl 1:16S–21.CrossRefPubMed
36.
Miller DH, Thompson AJ, Filippi M. Magnetic Resonance Studies of Abnormalities in the Normal Appearing White Matter and Grey Matter in Multiple Sclerosis. J Neurol. 2003;250(12):1407–19.CrossRefPubMed
37.
Schlaeger R, D’Souza M, Schindler C, Grize L, Kappos L, Fuhr P. Combined Evoked Potentials as Markers and Predictors of Disability in Early Multiple Sclerosis. Clin Neurophysiol. 2012;123(2):406–10.CrossRefPubMed
38.
Schlaeger R, Schindler C, Grize L, Dellas S, Radue EW, Kappos L, Fuhr P. Combined Visual and Motor Evoked Potentials Predict Multiple Sclerosis Disability after 20 Years. Mult Scler. 2014;20(10):1348–54.CrossRefPubMed
39.
Invernizzi P, Bertolasi L, Bianchi MR, Turatti M, Gajofatto A, Benedetti MD. Prognostic Value of Multimodal Evoked Potentials in Multiple Sclerosis: The Ep Score. J Neurol. 2011;258(11):1933–9.CrossRefPubMed
40.
Filippi M, Campi A, Mammi S, Martinelli V, Locatelli T, Scotti G, Amadio S, Canal N, Comi G. Brain Magnetic Resonance Imaging and Multimodal Evoked Potentials in Benign and Secondary Progressive Multiple Sclerosis. J Neurol Neurosurg Psychiatry. 1995;58(1):31–7.CrossRefPubMedPubMedCentral
41.
Comi G, Leocani L, Medaglini S, Locatelli T, Martinelli V, Santuccio G, Rossi P. Evoked Potentials in Diagnosis and Monitoring of Multiple Sclerosis. Electroencephalogr Clin Neurophysiol Suppl. 1999;49:13–8.PubMed
42.
Schlaeger R, D’Souza M, Schindler C, Grize L, Dellas S, Radue EW, Kappos L, Fuhr P. Prediction of Long-Term Disability in Multiple Sclerosis. Mult Scler. 2012;18(1):31–8.CrossRefPubMed
43.
Margaritella N, Mendozzi L, Tronci F, Colicino E, Garegnani M, Nemni R, Gilardi E, Pugnetti L. The Evoked Potentials Score Improves the Identification of Benign Ms without Cognitive Impairment. Eur J Neurol. 2013;20(10):1423–5.CrossRefPubMed
44.
Humm AM, Magistris MR, Truffert A, Hess CW, Rosler KM. Central Motor Conduction Differs between Acute Relapsing-Remitting and Chronic Progressive Multiple Sclerosis. Clin Neurophysiol. 2003;114(11):2196–203.CrossRefPubMed
Metadata
Title
Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis
Authors
Xavier Giffroy
Nathalie Maes
Adelin Albert
Pierre Maquet
Jean-Michel Crielaard
Dominique Dive
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2016
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-016-0608-1

Other articles of this Issue 1/2016

BMC Neurology 1/2016 Go to the issue

Research article

The effect of age on outcome after intra-arterial treatment in acute ischemic stroke: a MR CLEAN pretrial study

Study protocol

Motor imagery training for children with developmental coordination disorder – study protocol for a randomized controlled trial

Case report

Presynaptic neuromuscular transmission defect in the stiff person syndrome

Case report

Anomalous vascularization in a Wnt medulloblastoma: a case report

Case report

A de novo CTNNB1 nonsense mutation associated with syndromic atypical hyperekplexia, microcephaly and intellectual disability: a case report

Research article

The relevance of cortical lesions in patients with multiple sclerosis